3,3',5-Triiodo-L-thyronine

产品说明书

Print
Chemical Structure| 6893-02-3 同义名 : 三碘甲状腺原氨酸 ;Triiodothyronine; T3; NSC 80203; L-3,3’,5-Triiodothyronine; 3,3’,5-Triiodo-L-thyronine; Liothyronine
CAS号 : 6893-02-3
货号 : A267480
分子式 : C15H12I3NO4
纯度 : 98%
分子量 : 650.97
MDL号 : MFCD00002593
存储条件：

Pure form Keep in dark place,Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 : -
动物实验配方：
生物活性
靶点

  • JNK1

    JNK1, Kd:240 nM

  • JNK1

    JNK1, Kd:240 nM

  • JNK2

    JNK2, Kd:290 nM

  • JNK2

    JNK2, Kd:290 nM
描述 Liothyronine represents an active thyroid hormone variant. It acts as a powerful agonist for the thyroid hormone receptors TRα and TRβ, exhibiting Ki values of 2.33 nM for both hTRα and hTRβ, respectively[1].[2].[3]. Produced in accordance with GMP guidelines, Liothyronine (Triiodothyronine) (GMP), also known as Liothyronine, functions effectively as a supportive reagent in cell therapy production. It serves as a strong agonist for the thyroid hormone receptors TRα and TRβ with Ki values of 2.33 nM for each, hTRα and hTRβ, respectively[1].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02133040 - Active, not recruiting May 10, 2020 Denmark ... 展开 >> Aarhus University Hospital Aarhus, Region Midtjylland, Denmark, 8000 收起 <<
NCT02398344 Stroke Phase 1 Phase 2 Completed - Brazil ... 展开 >> University of Nove de Julho São Paulo, Brazil 收起 <<
NCT02733497 Hyperhidrosis Not Applicable Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.54mL

0.31mL

0.15mL

7.68mL

1.54mL

0.77mL

15.36mL

3.07mL

1.54mL
参考文献

[1]Lin KH, et al. Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. Cancer Lett. 1994 Oct 14;85(2):189-94.

[2]Bhat MK, et al. Conformational changes of human beta 1 thyroid hormone receptor induced by binding of 3,3',5-triiodo-L-thyronine. Biochem Biophys Res Commun. 1993 Aug 31;195(1):385-92.

[3]Hiroaki Shiohara, et al. Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia. Bioorg Med Chem. 2012 Jun 1;20(11):3622-34.

[4]Wang L, et al. Triiodothyronine and dexamethasone alter potassium channel expression and promote electrophysiological maturation of human-induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol. 2021 Dec;161:130-138.